Outlook Therapeutics (OTLK) Research & Development: 2015-2020
Historic Research & Development for Outlook Therapeutics (OTLK) over the last 6 years, with Sep 2020 value amounting to $7.6 million.
- Outlook Therapeutics' Research & Development rose 2.25% to $7.6 million in Q3 2020 from the same period last year, while for Sep 2020 it was $26.3 million, marking a year-over-year increase of 10.66%. This contributed to the annual value of $41.8 million for FY2024, which is 57.88% up from last year.
- As of Q3 2020, Outlook Therapeutics' Research & Development stood at $7.6 million, which was down 10.19% from $8.5 million recorded in Q2 2020.
- In the past 5 years, Outlook Therapeutics' Research & Development registered a high of $13.2 million during Q4 2016, and its lowest value of $402,402 during Q4 2017.
- For the 3-year period, Outlook Therapeutics' Research & Development averaged around $6.2 million, with its median value being $5.9 million (2019).
- Its Research & Development has fluctuated over the past 5 years, first tumbled by 96.96% in 2017, then spiked by 1,408.82% in 2018.
- Quarterly analysis of 5 years shows Outlook Therapeutics' Research & Development stood at $13.2 million in 2016, then crashed by 96.96% to $402,402 in 2017, then spiked by 1,408.82% to $6.1 million in 2018, then declined by 3.69% to $5.8 million in 2019, then climbed by 2.25% to $7.6 million in 2020.
- Its last three reported values are $7.6 million in Q3 2020, $8.5 million for Q2 2020, and $4.4 million during Q1 2020.